Blessy George

485 total citations
20 papers, 353 citations indexed

About

Blessy George is a scholar working on Pathology and Forensic Medicine, Pediatrics, Perinatology and Child Health and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Blessy George has authored 20 papers receiving a total of 353 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pathology and Forensic Medicine, 6 papers in Pediatrics, Perinatology and Child Health and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Blessy George's work include Chemotherapy-induced organ toxicity mitigation (7 papers), Pharmacological Effects and Toxicity Studies (4 papers) and Acute Kidney Injury Research (4 papers). Blessy George is often cited by papers focused on Chemotherapy-induced organ toxicity mitigation (7 papers), Pharmacological Effects and Toxicity Studies (4 papers) and Acute Kidney Injury Research (4 papers). Blessy George collaborates with scholars based in United States, Sweden and Belgium. Blessy George's co-authors include Lauren M. Aleksunes, Melanie S. Joy, Wen Xia, Cindy L. O’Bryant, Daniel W. Bowles, Susan L. Hogan, Yichun Hu, Andrew J. Gow, Changjiang Guo and Elena N. Atochina‐Vasserman and has published in prestigious journals such as Advanced Drug Delivery Reviews, The FASEB Journal and Free Radical Biology and Medicine.

In The Last Decade

Blessy George

18 papers receiving 345 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Blessy George United States 9 90 81 73 63 56 20 353
Katarzyna Stefańska Poland 11 38 0.4× 54 0.7× 46 0.6× 81 1.3× 46 0.8× 26 390
Liqin Zhou China 8 161 1.8× 54 0.7× 146 2.0× 33 0.5× 44 0.8× 16 401
Ademar Dantas da Cunha Júnior Brazil 7 190 2.1× 78 1.0× 60 0.8× 33 0.5× 59 1.1× 8 331
Zhao Hu China 14 110 1.2× 146 1.8× 106 1.5× 22 0.3× 19 0.3× 46 508
Sahar M. El-Haggar Egypt 12 52 0.6× 21 0.3× 121 1.7× 48 0.8× 64 1.1× 32 443
Ernie Harpur United States 8 50 0.6× 106 1.3× 66 0.9× 29 0.5× 29 0.5× 9 272
Abdellatif Achour Tunisia 13 62 0.7× 106 1.3× 86 1.2× 19 0.3× 19 0.3× 39 497
T Fuchs Germany 6 53 0.6× 158 2.0× 110 1.5× 22 0.3× 25 0.4× 9 399
Laura Healy United States 10 28 0.3× 87 1.1× 131 1.8× 18 0.3× 36 0.6× 15 334
Hongzhou Meng China 11 172 1.9× 27 0.3× 130 1.8× 48 0.8× 46 0.8× 18 535

Countries citing papers authored by Blessy George

Since Specialization
Citations

This map shows the geographic impact of Blessy George's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Blessy George with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Blessy George more than expected).

Fields of papers citing papers by Blessy George

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Blessy George. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Blessy George. The network helps show where Blessy George may publish in the future.

Co-authorship network of co-authors of Blessy George

This figure shows the co-authorship network connecting the top 25 collaborators of Blessy George. A scholar is included among the top collaborators of Blessy George based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Blessy George. Blessy George is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
George, Blessy, et al.. (2025). A Prospective Study on the Prescription Pattern of Anti-Epileptic Drugs in Pediatric Patients. Indian Journal of Pharmacy Practice. 18(3). 273–278.
2.
George, Blessy, et al.. (2024). Food‐Drug Effects and Pediatric Drug Development Studies Submitted to the US Food and Drug Administration, 2012‐2022. The Journal of Clinical Pharmacology. 64(6). 697–703. 4 indexed citations
3.
4.
Dallmann, André, et al.. (2024). Enhancing inclusivity in clinical trials: Model‐informed drug development for pregnant individuals in the era of personalized medicine. CPT Pharmacometrics & Systems Pharmacology. 13(11). 1824–1829. 4 indexed citations
5.
Li, Miao, et al.. (2023). Quantification of sertraline maternal/fetal ratio and amniotic fluid concentration using a pregnancy physiologically based pharmacokinetic model. British Journal of Clinical Pharmacology. 91(4). 1003–1015. 1 indexed citations
6.
George, Blessy, John T. Szilagyi, Melanie S. Joy, & Lauren M. Aleksunes. (2022). Regulation of renal calbindin expression during cisplatin‐induced kidney injury. Journal of Biochemical and Molecular Toxicology. 36(7). e23068–e23068. 7 indexed citations
7.
George, Blessy, Wen Xia, Edgar A. Jaimes, Melanie S. Joy, & Lauren M. Aleksunes. (2021). In Vitro Inhibition of Renal OCT2 and MATE1 Secretion by Antiemetic Drugs. International Journal of Molecular Sciences. 22(12). 6439–6439. 11 indexed citations
8.
George, Blessy, Wen Xia, Cindy L. O’Bryant, et al.. (2020). Time-dependent changes in kidney injury biomarkers in patients receiving multiple cycles of cisplatin chemotherapy. Toxicology Reports. 7. 571–576. 22 indexed citations
9.
George, Blessy, Annie Lumen, Christine Nguyen, et al.. (2020). Application of physiologically based pharmacokinetic modeling for sertraline dosing recommendations in pregnancy. npj Systems Biology and Applications. 6(1). 36–36. 21 indexed citations
10.
George, Blessy, Wen Xia, Edgar A. Jaimes, Melanie S. Joy, & Lauren M. Aleksunes. (2020). In Vitro Inhibition of Renal OCT2 and MATE1 Secretion by Antiemetic Drugs. Journal of the American Society of Nephrology. 31(10S). 117–118.
11.
Ibrahim, Mustafa E., Yichun Hu, Susan L. Hogan, et al.. (2018). Pharmacokinetic determinants of cisplatin-induced subclinical kidney injury in oncology patients. European Journal of Clinical Pharmacology. 75(1). 51–57. 29 indexed citations
12.
George, Blessy, et al.. (2017). Xenobiotic transporters and kidney injury. Advanced Drug Delivery Reviews. 116. 73–91. 96 indexed citations
13.
Hu, Yichun, Susan L. Hogan, Cindy L. O’Bryant, et al.. (2017). Pharmacogenomic Variants May Influence the Urinary Excretion of Novel Kidney Injury Biomarkers in Patients Receiving Cisplatin. International Journal of Molecular Sciences. 18(7). 1333–1333. 27 indexed citations
14.
Chiu, Alexander S., et al.. (2017). Remote management of low to intermediate risk chest pain: A case series. The American Journal of Emergency Medicine. 35(8). 1147–1149. 2 indexed citations
15.
George, Blessy, Melanie S. Joy, & Lauren M. Aleksunes. (2017). Urinary protein biomarkers of kidney injury in patients receiving cisplatin chemotherapy. Experimental Biology and Medicine. 243(3). 272–282. 45 indexed citations
16.
George, Blessy, et al.. (2016). Profiling of Kidney Injury Biomarkers in Patients Receiving Cisplatin: Time‐dependent Changes in the Absence of Clinical Nephrotoxicity. Clinical Pharmacology & Therapeutics. 101(4). 510–518. 35 indexed citations
17.
Guo, Changjiang, et al.. (2015). Role of NOS2 in pulmonary injury and repair in response to bleomycin. Free Radical Biology and Medicine. 91. 293–301. 33 indexed citations
18.
George, Blessy, et al.. (2015). Urinary KIM‐1 is a Novel Biomarker for Cisplatin‐Induced Subclinical Nephrotoxicity in Oncology Patients. The FASEB Journal. 29(S1). 2 indexed citations
19.
Auwera, P Van der, et al.. (1990). Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment. Antimicrobial Agents and Chemotherapy. 34(8). 1491–1497. 7 indexed citations
20.
George, Blessy, et al.. (1976). An evaluation of the self administration of DDS in Gudiyatham Taluk.. PubMed. 48(4 Suppl). 668–76. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Katarzyna Stefańska Breakdown of academic impact, for papers by Liqin Zhou Breakdown of academic impact, for papers by Ademar Dantas da Cunha Júnior Breakdown of academic impact, for papers by Zhao Hu Breakdown of academic impact, for papers by Sahar M. El-Haggar Breakdown of academic impact, for papers by Ernie Harpur Breakdown of academic impact, for papers by Abdellatif Achour Breakdown of academic impact, for papers by T Fuchs Breakdown of academic impact, for papers by Laura Healy Breakdown of academic impact, for papers by Hongzhou Meng
Rankless by CCL
2026